Last updated: May 26, 2026
Visipaque 320 (Iodixanol) Clinical Trials Update, Market Analysis, and Revenue Projection Through Patent and Generic Timelines
Executive summary: Visipaque 320 (iodixanol 320 mgI/mL), a nonionic, dimeric contrast medium for intravascular and other diagnostic imaging, faces near-term demand pressure from system-level utilization shifts and long-cycle procurement, but is still positioned as a category workhorse in CT and angiography workflows. Competitive dynamics remain dominated by lower-cost nonionic iodinated contrast alternatives across multiple SKUs and package sizes. A full clinical-trial and pipeline projection depends on whether specific “visipaque 320” products are being studied in new head-to-head or new-use protocols; without that granularity, market projection can only be anchored to category-level usage, mix, and likely pricing pressure rather than trial-driven step-function uptake.
What clinical trials are evaluating Visipaque 320 (iodixanol 320 mgI/mL) right now?
Featured snippet: Current publicly indexed “iodixanol 320” trials are usually conducted under the broader iodinated contrast or “iodixanol” umbrella and may not distinguish Visipaque 320 as a standalone investigational product. Where trials are listed, they commonly assess safety (adverse events), renal outcomes, injection tolerability, and imaging performance in CT or angiographic settings.
What trial endpoints matter most for iodixanol contrast media
In registrational and post-approval contrast medium studies, endpoints cluster around:
- Safety: treatment-emergent adverse events, hypersensitivity reactions, contrast-induced nephropathy or AKI proxies.
- Imaging quality: vessel opacification, lesion detectability scoring, CT attenuation consistency.
- Operational tolerance: injection pain, viscosity-handling usability, power injector compatibility.
What patient populations are most frequently studied
- Renal impairment risk groups: patients with chronic kidney disease or diabetes where AKI risk is a key comparator.
- Cardiovascular imaging: angiography and related interventional radiology settings.
- CT workflows: CT angiography and contrast-enhanced CT.
How trial results translate into commercial adoption
Because contrast media are typically interchangeable substitutes under hospital formularies, new clinical data usually drives:
- Formulary switches when safety or renal outcome differentiation is material.
- Utilization standardization where workflow fit (packaging, delivery system) reduces waste and dosing errors.
Is Visipaque 320 still gaining market share, or is it losing volume to other iodinated contrast agents?
Featured snippet: Visipaque 320’s category exposure is stable, but volume growth tends to track imaging utilization and contracting pricing rather than trial-driven expansion.
Category substitution pressures
Hospitals standardize on a small set of nonionic iodinated contrast SKUs, typically selecting based on:
- Net price after rebates and tenders
- Package size and dosing convenience
- Supply reliability
- Formulary history and protocol lock-in
Visipaque 320 competes primarily against other nonionic iodinated contrasts (including lower-cost generics and branded equivalents depending on jurisdiction).
Mix effects that favor or hurt iodixanol 320
- Favoring factors: protocols that prioritize iso-osmolar contrast media in higher-risk renal populations.
- Pressuring factors: system-wide standardization on specific formularies that may move toward cost-effective agents.
How big is the Visipaque 320 opportunity in CT and angiography, and what does the demand base look like?
Featured snippet: The addressable demand base for iodixanol 320 is tied to CT contrast usage and angiography contrast consumption in hospital and outpatient imaging centers.
Primary demand drivers
- CT utilization growth (including CT angiography share)
- Interventional radiology volume
- Aging demographics and comorbidity burden that keeps contrast use clinically relevant
- Guideline adherence to contrast safety practices
Market constraint factors
- Renal-protection protocols can reduce contrast dosing in lower acuity settings.
- Cost containment in hospital procurement increases pricing pressure.
- Shorter inventory turns can favor agents with better tender and supply terms.
What is the competitive landscape for iodixanol 320 mgI/mL?
Featured snippet: Visipaque 320 competes in the nonionic iodinated contrast market against other iso-osmolar or low-osmolar agents, with selection often determined by net contracting economics.
Key competitive vectors
- Iso-osmolar differentiation claims (renal safety positioning)
- Injection and workflow compatibility
- Branding plus tender pricing
- Availability and allocation risk
How procurement structures influence sales
- Group purchasing organization (GPO) and IDN contracts can lock in SKUs.
- Tenders often shift volumes to the lowest net price that meets clinical protocols.
- Inventory management affects reorder cycles, which can distort month-to-month sales.
When does Visipaque 320 lose exclusivity, and what generic entry risks exist?
Featured snippet: For older contrast media, exclusivity is typically determined by a combination of composition-of-matter, formulation/process patents (if any remain), and data exclusivity periods that may not align with today’s product brand. Generic and authorized equivalents in iodinated contrast are common due to long commercialization history.
Exclusivity and patent reality check for older iodixanol products
For marketed iodixanol products, competitive pressure from generics is usually already present depending on market and regulatory status. New “generic entry” risks depend on:
- Whether a specific Visipaque 320 presentation still has remaining patent or exclusivity coverage.
- Whether the market uses substitutes that are already approved.
Paragraph IV and settlement-driven timelines
Paragraph IV certification is a framework tied to FDA brand-versus-generic dynamics for ANDA applicants. For iodixanol contrast, the practical question is whether any active listed Orange Book patents still block a specific dosage form/presentation. Without Orange Book patent mapping to the exact Visipaque 320 presentations, a reliable Paragraph IV timeline can’t be established here.
What is the Orange Book status of Visipaque 320 (iodixanol 320 mgI/mL)?
Featured snippet: Orange Book status requires mapping to specific NDA/ANDA references and listed patents by active ingredient and presentation. A complete, accurate status table cannot be produced without the exact NDA number and patent list entries for the specific Visipaque 320 strength/presentation.
What to look for in the Orange Book entry
- NDA number(s) tied to iodixanol 320
- Listed patents (drug substance, drug product, method of use, packaging, manufacturing)
- Patent expiration dates
- Patent certifications (if any) for approved generics
What formulations and delivery systems are protected for Visipaque 320?
Featured snippet: For contrast media, protected elements typically include drug product composition, concentration-specific formulation characteristics, and sometimes manufacturing processes that preserve stability and reduce impurities.
Formulation IP categories relevant to iodinated contrast
- Composition constraints: stabilization, viscosity tuning, and impurities.
- Process constraints: manufacturing controls that affect iodixanol quality attributes.
- Packaging/handling: container and stopper compatibility, per-presentation characteristics.
Why this matters for generic switching
If protection is presentation-specific (container type, volume per vial/bag), switchovers can be delayed even when composition is not.
How does Visipaque 320 compare with other iodixanol products and with alternative contrast media?
Featured snippet: Visipaque 320 is a 320 mgI/mL concentration iso-osmolar iodixanol contrast. Clinical comparisons in practice often focus on AKI-risk populations and imaging quality parity across CT and angiography use cases.
Comparison dimensions that drive clinical and purchasing choice
- Renal risk positioning
- Osmolality class
- Injection tolerability
- Imaging performance at standard volumes
- Injection setup compatibility
What does the market projection for Visipaque 320 assume about pricing, volume, and share?
Featured snippet: Projections for mature iodinated contrast products typically assume modest volume growth linked to imaging utilization and continued unit-cost erosion driven by contracting and substitution.
Projection model structure (what drives the numbers)
A credible forward projection for a marketed contrast medium usually decomposes into:
- Volume: procedures using contrast times average iodixanol 320 dose utilization.
- Mix: shift toward/away from 320 mgI/mL and toward different pack sizes.
- Price realization: net price after rebates, tender outcomes, and competitor discounting.
Base-case outcome (category-consistent)
- Net sales: likely grow at or below procedure-volume growth due to net price pressure.
- Gross margin: supported by scale but constrained by procurement dynamics.
- Share: stable unless a tender awards a substitute agent or protocol changes.
What litigation or regulatory events could affect Visipaque 320’s commercial outlook?
Featured snippet: Litigation and regulatory events that can affect iodinated contrast brands are usually tied to patent challenges, label changes, or manufacturing/quality actions. A reliable litigation map requires case-level identification against the specific NDA and listed patents.
Regulatory risk categories
- Labeling updates affecting renal safety language or hypersensitivity warnings
- Quality/CMC actions that constrain supply
- Distribution interruptions tied to manufacturing sites
Market risk categories
- Tender-driven contract displacement
- Switch protocols when alternative agents are adopted for cost or logistics reasons
Key Takeaways
- Visipaque 320 (iodixanol 320 mgI/mL) demand is primarily driven by CT and angiography procedure volumes rather than rapid trial-driven adoption.
- Competitive pressure is structurally linked to hospital procurement, where net price and tender awards often outweigh incremental clinical differences.
- Generic substitution risk is common in older iodinated contrast categories; whether “additional” generic entry events occur depends on remaining Orange Book coverage for specific Visipaque 320 presentations.
- A reliable exclusivity, litigation, and patent-expiration timeline requires exact NDA/presentation mapping and Orange Book patent listing, which is not provided in the prompt.
FAQs
- What renal safety claims do iodixanol 320 products typically make versus low-osmolar contrast?
- How do hospital tenders decide between iodixanol 320 and competing nonionic iodinated contrast media?
- What manufacturing quality risks are most important for iodinated contrast supply continuity?
- Do contrast dosing protocols change unit consumption of iodixanol 320 by patient risk tier?
- How should an investor model revenue for mature contrast media under pricing erosion from generics?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-26).
- ClinicalTrials.gov. (Accessed 2026-05-26).
